Skip to content
OpenCapital
Get started

Danaher DHR Life Sciences — Operating Income (Loss)

Other segment segments

Diagnostics
$713M—
Biotechnology
$390M—

Similar metrics at other companies

Ashland logo
ASHLife Sciences — Operating Income
$35M+25.0%
Thermo Fisher Scientific logo
TMOLife Sciences Solutions — Operating Income (Loss)
$1.04B+13.2%
VAT
VATELife Sciences — Income from operations
-$2.2M+26.7%
RCM Technologies logo
RCMTLife Sciences Data Solutions — Operating Income
$2.05M-3.7%
STERIS logo
STELife Sciences: — Segment operating income
$61.8M+6.4%
STERIS logo
STELife Sciences: — Operating Income (Loss), Before Adjustments
$61.8M+6.4%

Other financials

Income statement

See full
Revenue$6.3B+5.5%
Gross profit$3.6B+2.5%
Operating income$1.1B+48.3%
Net income$870.0M+56.8%
EPS (diluted)$1.23+59.7%

Balance sheet

See full
Cash & equivalents$4.3B+47.0%
Total debt$27.9B+50.1%
Total equity$52.6B+0.5%
Total assets$92.4B+13.2%

Cash flow

See full
Operating cash flow$1.5B+14.6%
CapEx$269.0M+8.5%
Free cash flow$1.3B+16.1%

Valuation

See full
Market cap$134.62B-7.4%
Enterprise value$158.13B-1.7%
P/E33.6×-9.0×
P/S5.4×-0.7×

Profitability

See full
Gross margin58.5%-1.1pp
Operating margin20.4%+2.0pp
Net margin15.9%+1.7pp
FCF margin21.8%+1.5pp

Returns & leverage

See full
Return on equity7.6%+1.0pp
Debt / equity0.5×+0.2×
Current ratio1.7×0.0×

Where this comes from

Reported directly by Danaher in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Danaher’s 10-Q, filed July 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about Danaher's life sciences — operating income (loss).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Danaher's life sciences — operating income (loss)?
Danaher (DHR) reported life sciences — operating income (loss) of $244M in Q2 2026.
How has Danaher's life sciences — operating income (loss) changed year-over-year?
Danaher's life sciences — operating income (loss) increased by 202.1% year-over-year, from -$239M to $244M.
What is the long-term trend for Danaher's life sciences — operating income (loss)?
Over 2 years (2023 to 2025), Danaher's life sciences — operating income (loss) has grown at a -34.4% compound annual growth rate (CAGR), from $1.21B to $520M.
What does life sciences — operating income (loss) mean?
The profit or loss generated by the Life Sciences segment after deducting operating expenses from revenue. This metric excludes interest, taxes, and corporate-level allocations, focusing strictly on the segment's ability to generate profit from its core business activities. It is the primary measure of the segment's operational health and management effectiveness.